VRP.L Share News (VRP)
VRP Share
VRP Share
VRP Share
VRP Share
VRP
VRP Share
VRP Broker
VRP Directors
VRP Financial
VRP
VRP Short
VRPWed, 29th May 2019 16:23
AGA Rangemaster: N+1 Singer ups target price from 175p to 192p and maintains a buy recommendation. Aggreko: JP Morgan lowers target price from 1542p to 1536p and maintains a neutral rating. Goldman Sachs increases target price from 1876p to 1950p and keeps a buy recommendation. Numis upgrades to re
Read more
LONDON (Alliance News) - Verona Pharma PLC Thursday said it intends to raise up to GBP14 million before expenses in a share placing, subscription, and open offer, which it said it will use to fund further development of its RPL554 drug. The drug development company focuses on medicines to t
Read moreAssociated British Foods: Barclays downgrades to equal-weight with a target price of 2100p. Bovis Homes Group: Deutsche Bank moves target price from 1001p to 1008p maintaining a buy recommendation. British Land: Deutsche Bank downgrades to sell with a target price of 520p. British Sky Broadcastin
Read moreVerona Pharma on Thursday said Chief Financial Officer (CFO) Danny Lowe would be replaced by Richard Bungay with immediate effect. Bungay will work part-time at the respiratory treatments specialist at first and Lowe will work with him for an interim period to make sure there is a smooth handover.
Read moreGraham Mackay, the Chairman of SABMiller who is currently on a medical leave of absence due to a brain tumour, has sold over 11m pounds-worth of shares in the company. Mackay sold a total of 350,000 shares between July 16-18th through three separate transactions, the firm revealed on Tuesday. He so
Read moreThe Chief Executive of Advanced Oncotherapy, a provider of new technology for innovative and patient-focused cancer treatments, has this week purchased three lots of shares in the group, taking his stake to just under 69.4m shares. On Thursday Sinclair purchased one round of 8.075m shares at 1.59p
Read moreJohn Whybrow, the Chairman of AZ Electronic Materials, which on Tuesday tanked after it issued a warning on full year revenue, has shown his faith in the chemicals company by enlarging his shareholding. Whybrow acquired 40,000 shares at 254p each for a total trade value of £101,600, taking his sta
Read moreRespiratory diseases specialist Verona Pharma has hailed a positive outcome of a clinical trial of its lead drug candidate, the snappily-named RPL554. The data showed that a single dose of RPL554 in spray form administered to patients with chronic obstructive pulmonary disease (COPD) produced a ra
Read moreTransense Technologies, which provides sensor systems for the transportation and industrial markets, has reported that its trading division, Translogik, has received an initial order for its iTrack Tyre Temperature and Pressure Monitoring Systems for mining and off-the-road vehicles from its Indones
Read moreShares in Lighthouse Group, the financial advice and wealth management group, plunged on Monday after the company proposed to cancel its listing on AIM. The group must receive approval from shareholders representing at least three-quarters of the company's shares for the cancellation to be approved.
Read moreVerona Pharma, respiratory diseases treatment developer, is initiating a new higher dose trial of its lead drug, RPL554, in patients with asthma, after receiving the go-ahead from the Dutch authorities. The company also announced that it has completed proof of concept trials on delivering RPL554 vi
Read moreLONDON (Dow Jones)--Verona Pharma PLC (VRP.LN), an AIM quoted drug discovery company, said Monday licensing discussions continue to advance with potential licensees for its RPL554 cough project and it plans three clinical trials to add value to licensing package for RPL554. MAIN FACTS: -Has
Read more